Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients

Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients
Results of a Phase 3 clinical trial show that Lynparza (olaparib) tablets met the primary goal of significantly improving the objective response rate, which is the percentage of patients whose cancer shrinks or disappears after treatment. The results also found that Lynparza extended the time advanced ovarian cancer patients lived without the disease progressing. The SOLO-3 study (NCT02282020), which compared Lynparza to standard of care chemotherapy, included patients with a germline (inherited) mutation in the BRCA genes and whose disease returned after two or more prior lines of chemotherapy. “We are very excited about SOLO-3, which is the first Phase III trial for a PARP inhibitor to demonstrate a positive result versus chemotherapy in advanced ovarian cancer where effective options are needed. We look forward to sharing the full results at a forthcoming medical meeting,” Sean Bohen, said in a press release. Bohen is executive vice president of global medicines development and chief medical officer at AstraZeneca,. Lynparza, which is jointly developed by AstraZeneca and Merck (MSD outside North America and Canada) is a PARP enzyme inhibitor that works by preventing cells from
Subscribe or to access all post and page content.

Tagged , , , , , .

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Leave a Comment

Your email address will not be published. Required fields are marked *